GE HealthCare (GEHC)
Makes medical imaging systems, diagnostic agents, patient monitors, and related software and services.
Something off on this page? Send us feedback.
Sells medical imaging, ultrasound and image-guided systems, contrast media and radiopharmaceuticals, and patient-monitoring and life-support equipment. Revenue combines capital equipment with service contracts, software and recurring consumables across a global hospital customer base.
Organized around Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions, supplies CT, MR, molecular imaging and X-ray systems; specialized ultrasound and image-guided technologies; contrast media and radiopharmaceuticals; and patient-monitoring, diagnostic-cardiology, maternal-infant and anesthesia equipment. AI-enabled software, cloud tools and enterprise imaging connect parts of these clinical workflows.
Sells globally to hospitals, health systems and researchers through direct teams and distributors. Its commercial model pairs equipment with long-term maintenance, lifecycle upgrades, software subscriptions and repeat-use diagnostic agents. Demand depends on provider capital budgets and reimbursement; products face market-specific authorization, quality and supply-chain requirements.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 22, 2026 | Needham | Initiate | Rating: —Target: — | Target: $93 |
| Jul 30, 2026 | Evercore ISI | Reiterate | Rating: —Target: $80 | Target: $84 |
| Jul 29, 2026 | BTIG | Reiterate | Rating: —Target: $75 | Target: $79 |
| Jul 16, 2026 | UBS | Reiterate | Rating: —Target: $69 | Target: $67 |
| Jul 13, 2026 | BTIG | Reiterate | Rating: —Target: $91 | Target: $75 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $2.11B · Total debt $10.09B · Total assets $37.25B · Shareholders' equity $10.98B
- Revenue
- $5.30B
- Operating income
- $739.0M
- Net income
- $573.0M
HistoryDividendAnnual yield
| Institutions | 87.96% | 397.32M shares | |
|---|---|---|---|
| 1,267 holders · as of Jun 30, 2026 | |||
| Insiders | 0.25% | 1.15M shares | |
| 24 holders · as of Sep 16, 2026 | |||
| Strategic holders | 7.22% | 32.63M shares | |
| 1 holder · as of Mar 15, 2024 | |||
| Other | 4.57% | 20.58M shares | |
| remainder | |||
451.69M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Dodge & CoxInstitution | 8.38% | 37.86M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 8.30% | 37.47M | as of Jun 30, 2026 |
General Electric Co1,2Strategicother: Former 10% Owner | 7.22% | 453.93M | filed Mar 15, 2024 |
Vanguard Capital Management LLCInstitution | 6.58% | 29.72M | as of Jun 30, 2026 |
State Street CorpInstitution | 4.62% | 20.86M | as of Jun 30, 2026 |
- General Electric Co's transaction reports restate only vehicles that traded; the 2023 ownership statement (453.93M) less the 421.29M net shares sold since is used instead.
- General Electric Co reports a block also reported by Vanguard Capital Management LLC; it is counted once, under Vanguard Capital Management LLC.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 22, 2026 | Kevin Lobo | director | +10,000 | $64.18 |
| May 12, 2026 | Rodney F. Hochman | director | +1,618 | $62.03 |
| May 8, 2026 | Watkin Phoebe L. Yang | director | +1,000 | $63.01 |
| May 6, 2026 | William J. Stromberg | director | +1,000 | $61.69 |
| May 6, 2026 | H. Lawrence Jr Culp | director | +80,805 | $61.88 |
- Philips (ADR)
Competes across imaging, cardiovascular ultrasound, and patient monitoring.
- Lantheus
Radiopharmaceutical pure-play; PYLARIFY PSMA PET overlaps with GEHC Flyrcado.
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| GE HealthCare | $66.27 | −0.02% | $29.27B | 18.8 | 12.7 | 1.4 | +5.8% |
| Philips (ADR) | $24.97 | −0.06% | $24.34B | 18.7 | 13.0 | 1.2 | −2.8% |
| Lantheus | $100.00 | −0.01% | $6.53B | 24.2 | 17.8 | 4.2 | +2.7% |
| Median | 21.5 | 15.4 | 2.7 | −0.1% |